$2.15
+0.00 (+0.00%)
Open$2.14
Previous Close$2.15
Day High$2.17
Day Low$2.13
52W High$3.44
52W Low$2.09
Volume—
Avg Volume32.4K
Market Cap66.77M
P/E Ratio—
EPS$-1.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+456.7% upside
Current
$2.15
$2.15
Target
$11.97
$11.97
$8.96
$11.97 avg
$15.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 51.54M | 48.92M | 53.08M |
| Net Income | -6,374,638 | -6,659,114 | -5,888,081 |
| Profit Margin | -12.4% | -13.6% | -11.1% |
| EBITDA | -7,191,271 | -7,364,625 | -7,497,793 |
| Free Cash Flow | -8,326,283 | -5,338,476 | -7,416,749 |
| Rev Growth | +3.4% | -7.2% | +0.9% |
| Debt/Equity | 0.61 | 0.70 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |